drugset / Trial / NCT00419419

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419 ↗

Phase 3 Completed 80 enrolled MediQuest Therapeutics
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Timeline

Start
2006-12
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitroglycerin Unknown — Topical